- published: 23 May 2016
- views: 931
Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City.
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
BMS' primary R&D sites are located in Lawrence Township (formerly Squibb, near Princeton) and Wallingford, Connecticut (formerly Bristol-Myers), with other sites in Hopewell and New Brunswick, New Jersey, and in Braine-l'Alleud, Belgium, Tokyo, Japan and Bangalore, India.
Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York. Squibb was known as a vigorous advocate of quality control and high purity standards within the fledgling pharmaceutical industry of his time, at one point self-publishing an alternative to the U.S. Pharmacopeia (Squibb's Ephemeris of Materia Medica) after failing to convince the American Medical Association to incorporate higher purity standards. Mentions of the Materia Medica, Squibb products, and Edward Squibb's opinion on the utility and best method of preparation for various medicants are found in many medical papers of the late 1800s. Squibb Corporation served as a major supplier of medical goods to the Union Army during the United States Civil War, providing portable medical kits containing morphine, surgical anesthetics, and quinine for the treatment of malaria (which was endemic in most of the eastern United States at that time).
Introduction by: Thomas Lynch, MD, CEO, Mass General Physician's Organization Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC Giovanni Caforio, MD, CEO, Bristol-Myers Squibb
Bristol-Myers Squibb is building a state-of-the-art facility in Dublin, Ireland, to expand our biologics manufacturing capacity, and to continue to innovate and strengthen biologics, immuno-oncology and cancer treatment drug development. Currently under construction, the plant is built on the grounds of the company’s previous bulk pharmaceutical manufacturing plant. Completion of this facility is estimated to be complete and operational in 2019. Bristol-Myers Squibb has a healthy pipeline of products and is dedicated to providing excellent opportunities for growth and career development. With Bristol-Myers Squibb, the work you do can be powerful and life-changing. Uncover new stories, and discover life-changing opportunities. To find out more about our work and careers visit in Ireland: ...
Billionaire activist investor Carl Icahn has taken a stake in pharmaceutical giant Bristol Myers-Squibb. WSJ's David Benoit and Tanya Rivero discuss the reasons behind Icahn's move, which came on the same day the company made efforts to appease another activist investor. Photo: Reuters Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy More from the Wall Street Journal: Visit WSJ.com: http://www.wsj.com Follow WSJ on Facebook: http://www.facebook.com/wsjvideo Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJvideo Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
CNBC's Jim Cramer and David Faber weigh in on Carl Icahn stepping up the pressure on Bristol-Myers. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Carl Icahn Takes Stake In Bristol-Myers Squibb | CNBC
At Bristol-Myers Squibb, we are committed to being a responsible global citizen, and our new state-of-the-art Princeton Pike facility in Lawrence Township, New Jersey was built with the environment in mind. Read more: http://bit.ly/2p3vyaf. Join Bristol-Myers Squibb Online: Website: https://www.bms.com Twitter: https://www.twitter.com/BMSnews Facebook: https://www.facebook.com/bristolmyerssquibb LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb
At Bristol-Myers Squibb, we’re excited to unveil Live & Science Magazine on the new BMS.com. This editorial brings to life our steadfast commitment to humanity and science. This first issue delves deeper into Kentucky LEADS, a collaborative funded by a grant from the BMS Foundation. Learn more at http://www.bms.com/magazine. Join Bristol-Myers Squibb Online: Website: https://www.bms.com Twitter: https://www.twitter.com/BMSnews Facebook: https://www.facebook.com/bristolmyerssquibb LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb
In this video, Bristol-Myers Squibb's Scott Biller, John Dickson, Michael Lawrence, David Magnin, Michael Poss, Jeffrey Robl, and Joseph Tino were honored as 2014 ACS Heroes of Chemistry for the discovery of Lomitapide (Juxtapid®), a novel inhibitor of microsomal triglyceride transfer protein (MTP) to treat homozygous familial hypercholesterolemia. The drug was later in-licensed by Aegerion.
Learn how data collected from routine medical practice settings can help healthcare providers better understand how a treatment may work for patients. Join Bristol-Myers Squibb Online: Website: http://www.bms.com Facebook: http://www.facebook.com/bristolmyerssquibb Twitter: http://www.twitter.com/BMSnews LinkedIn: http://www.linkedin.com/company/bristol-myers-squibb
Datamatrix coding of extreme volumes (up to 400 packages/minute) by machines tailored to the pharmaceutical giant's needs/industry requirements, and combining various functionalities. Learn more at: http://www.zetes.com/en/fiches/corporate/solutions-services/goods-id/serialisation-and-label-identification-at-high-speed-production-lines.cfm
At Biotech Week Boston 2016 in Boston, MA, we sat down with Brian Bell, Ph.D., Manager, Process Microbiology, Process Lifecycle Management, Manufacturing Science & Technology at Bristol-Myers Squibb. Dr. Bell was also a presenter on "Microbial Monitoring for Biological Drug Substance - An Industry Perspective" at the co-located BioProcess International Conference & Exhibition.
The Bristol-Myers Squibb Foundation is engaged in more than 100 active global projects to improve healthcare for nearly 1.5 million people worldwide. The Foundation develops initiatives locally and shares them globally to promote health equity and improve health outcomes for populations most vulnerable to serious diseases. Click here to learn more about the work that the Bristol-Myers Squibb Foundation is doing around the globe: http://www.bms.com/foundation/Pages/home.aspx Join Bristol-Myers Squibb Online: Website: http://www.bms.com Facebook: http://www.facebook.com/bristolmyerssquibb Twitter: http://www.twitter.com/BMSnews LinkedIn: http://www.linkedin.com/company/bristol-myers-squibb
Bristol-Myers Squibb leads the field in Immuno-Oncology research. Your body has always been able to take on illnesses and now it's taking on a powerful enemy – cancer. Find out more about our work in Immuno-Oncology on our website: http://www.ImmunoOncologyNow.com, intended for U.S. audiences. Or talk to your doctor today. Join Bristol-Myers Squibb Online: Website: http://www.bms.com Facebook: http://www.facebook.com/bristolmyerssquibb Twitter: http://www.twitter.com/BMSnews LinkedIn: http://www.linkedin.com/company/bristol-myers-squibb
Did Bristol-Myers Squibb's success stem from the mass murder of Jews in WW2 Germany? IG Farben was a powerful cartel comprised of several German chemical companies which experimented without mercy on Jewish prisoners as Hitler commanded, inside the WW2 concentration camps, testing dangerous drugs and killing their unwilling guinea pig patients. Two weeks after Germany gave up the war, Washington DC received a scientist from Germany. This was the beginning of the United State's Project Paperclip which was created to exploit the knowledge of Nazi scientists. This shows that the US Military was interested in what they were working on over there. A few years later, 24 executives from IG Farben were convicted of mass murder, slavery and other crimes against humanity. However, in less than 7 ...
Compere Jonathan McCrea speaks with MIke Furlong, Executive DIrector, Cruiserath Biologics, BMS, Mairead Looby, Director, Manufacturing Science and Technology, BMS, Donagh Walls, Associate Director, QC Site Operations, BMS, and Lisa Cahill, HR Manager, BMS.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said investors need to reassess shares of Bristol Myers amid reports that its lung cancer treatment Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
At Bristol-Myers Squibb, patients are at the center of everything we do. When employees are asked what motivates them, the answer is always the same: we work together for patients. Growing up, Colleen’s older brother was the strongest person she knew—and their bond was even stronger. Then he was diagnosed with cancer at age 25. The disease and resulting treatments weakened him to the point where he was unrecognizable to Colleen. At Bristol-Myers Squibb, Colleen is proud of her role in helping the company to ease the pain felt by family members when their loved ones are affected by cancer and other serious diseases.
Speaking to Siliconrepublic.com, Lisa Cahill, HR manager at BMS Cruiserath Biologics, talks about the new BMS plant, the roles currently on offer at the Cruiserath facilities, and what she looks for from candidates. Looking for STEM jobs in Ireland? Check out our careers section for information on companies hiring right now: https://www.siliconrepublic.com/careers For more, see https://www.siliconrepublic.com Follow us on Twitter: https://twitter.com/siliconrepublic Like us on Facebook: https://www.facebook.com/siliconrepublic
At Bristol-Myers Squibb, patients are at the center of everything we do. BMS Tampa is one example of a dynamic workplace working together for patients. Our center in Tampa manages operations in R&D;, Business Operations, Finance, IT, Procurement, Marketing and Human Resources — with more roles still to come. Learn more at http://www.tampa.bms.com. Join Bristol-Myers Squibb Online: Website: https://www.bms.com Twitter: https://www.twitter.com/BMSnews Facebook: https://www.facebook.com/bristolmyerssquibb LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb
Introduction by: Thomas Lynch, MD, CEO, Mass General Physician's Organization Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC Giovanni Caforio, MD, CEO, Bristol-Myers Squibb
Bristol-Myers Squibb is building a state-of-the-art facility in Dublin, Ireland, to expand our biologics manufacturing capacity, and to continue to innovate and strengthen biologics, immuno-oncology and cancer treatment drug development. Currently under construction, the plant is built on the grounds of the company’s previous bulk pharmaceutical manufacturing plant. Completion of this facility is estimated to be complete and operational in 2019. Bristol-Myers Squibb has a healthy pipeline of products and is dedicated to providing excellent opportunities for growth and career development. With Bristol-Myers Squibb, the work you do can be powerful and life-changing. Uncover new stories, and discover life-changing opportunities. To find out more about our work and careers visit in Ireland: ...
Billionaire activist investor Carl Icahn has taken a stake in pharmaceutical giant Bristol Myers-Squibb. WSJ's David Benoit and Tanya Rivero discuss the reasons behind Icahn's move, which came on the same day the company made efforts to appease another activist investor. Photo: Reuters Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy More from the Wall Street Journal: Visit WSJ.com: http://www.wsj.com Follow WSJ on Facebook: http://www.facebook.com/wsjvideo Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJvideo Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
CNBC's Jim Cramer and David Faber weigh in on Carl Icahn stepping up the pressure on Bristol-Myers. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Carl Icahn Takes Stake In Bristol-Myers Squibb | CNBC
At Bristol-Myers Squibb, we are committed to being a responsible global citizen, and our new state-of-the-art Princeton Pike facility in Lawrence Township, New Jersey was built with the environment in mind. Read more: http://bit.ly/2p3vyaf. Join Bristol-Myers Squibb Online: Website: https://www.bms.com Twitter: https://www.twitter.com/BMSnews Facebook: https://www.facebook.com/bristolmyerssquibb LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb
At Bristol-Myers Squibb, we’re excited to unveil Live & Science Magazine on the new BMS.com. This editorial brings to life our steadfast commitment to humanity and science. This first issue delves deeper into Kentucky LEADS, a collaborative funded by a grant from the BMS Foundation. Learn more at http://www.bms.com/magazine. Join Bristol-Myers Squibb Online: Website: https://www.bms.com Twitter: https://www.twitter.com/BMSnews Facebook: https://www.facebook.com/bristolmyerssquibb LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb
In this video, Bristol-Myers Squibb's Scott Biller, John Dickson, Michael Lawrence, David Magnin, Michael Poss, Jeffrey Robl, and Joseph Tino were honored as 2014 ACS Heroes of Chemistry for the discovery of Lomitapide (Juxtapid®), a novel inhibitor of microsomal triglyceride transfer protein (MTP) to treat homozygous familial hypercholesterolemia. The drug was later in-licensed by Aegerion.
Learn how data collected from routine medical practice settings can help healthcare providers better understand how a treatment may work for patients. Join Bristol-Myers Squibb Online: Website: http://www.bms.com Facebook: http://www.facebook.com/bristolmyerssquibb Twitter: http://www.twitter.com/BMSnews LinkedIn: http://www.linkedin.com/company/bristol-myers-squibb
Datamatrix coding of extreme volumes (up to 400 packages/minute) by machines tailored to the pharmaceutical giant's needs/industry requirements, and combining various functionalities. Learn more at: http://www.zetes.com/en/fiches/corporate/solutions-services/goods-id/serialisation-and-label-identification-at-high-speed-production-lines.cfm
At Biotech Week Boston 2016 in Boston, MA, we sat down with Brian Bell, Ph.D., Manager, Process Microbiology, Process Lifecycle Management, Manufacturing Science & Technology at Bristol-Myers Squibb. Dr. Bell was also a presenter on "Microbial Monitoring for Biological Drug Substance - An Industry Perspective" at the co-located BioProcess International Conference & Exhibition.
The Bristol-Myers Squibb Foundation is engaged in more than 100 active global projects to improve healthcare for nearly 1.5 million people worldwide. The Foundation develops initiatives locally and shares them globally to promote health equity and improve health outcomes for populations most vulnerable to serious diseases. Click here to learn more about the work that the Bristol-Myers Squibb Foundation is doing around the globe: http://www.bms.com/foundation/Pages/home.aspx Join Bristol-Myers Squibb Online: Website: http://www.bms.com Facebook: http://www.facebook.com/bristolmyerssquibb Twitter: http://www.twitter.com/BMSnews LinkedIn: http://www.linkedin.com/company/bristol-myers-squibb
Bristol-Myers Squibb leads the field in Immuno-Oncology research. Your body has always been able to take on illnesses and now it's taking on a powerful enemy – cancer. Find out more about our work in Immuno-Oncology on our website: http://www.ImmunoOncologyNow.com, intended for U.S. audiences. Or talk to your doctor today. Join Bristol-Myers Squibb Online: Website: http://www.bms.com Facebook: http://www.facebook.com/bristolmyerssquibb Twitter: http://www.twitter.com/BMSnews LinkedIn: http://www.linkedin.com/company/bristol-myers-squibb
Did Bristol-Myers Squibb's success stem from the mass murder of Jews in WW2 Germany? IG Farben was a powerful cartel comprised of several German chemical companies which experimented without mercy on Jewish prisoners as Hitler commanded, inside the WW2 concentration camps, testing dangerous drugs and killing their unwilling guinea pig patients. Two weeks after Germany gave up the war, Washington DC received a scientist from Germany. This was the beginning of the United State's Project Paperclip which was created to exploit the knowledge of Nazi scientists. This shows that the US Military was interested in what they were working on over there. A few years later, 24 executives from IG Farben were convicted of mass murder, slavery and other crimes against humanity. However, in less than 7 ...
Compere Jonathan McCrea speaks with MIke Furlong, Executive DIrector, Cruiserath Biologics, BMS, Mairead Looby, Director, Manufacturing Science and Technology, BMS, Donagh Walls, Associate Director, QC Site Operations, BMS, and Lisa Cahill, HR Manager, BMS.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said investors need to reassess shares of Bristol Myers amid reports that its lung cancer treatment Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
At Bristol-Myers Squibb, patients are at the center of everything we do. When employees are asked what motivates them, the answer is always the same: we work together for patients. Growing up, Colleen’s older brother was the strongest person she knew—and their bond was even stronger. Then he was diagnosed with cancer at age 25. The disease and resulting treatments weakened him to the point where he was unrecognizable to Colleen. At Bristol-Myers Squibb, Colleen is proud of her role in helping the company to ease the pain felt by family members when their loved ones are affected by cancer and other serious diseases.
Speaking to Siliconrepublic.com, Lisa Cahill, HR manager at BMS Cruiserath Biologics, talks about the new BMS plant, the roles currently on offer at the Cruiserath facilities, and what she looks for from candidates. Looking for STEM jobs in Ireland? Check out our careers section for information on companies hiring right now: https://www.siliconrepublic.com/careers For more, see https://www.siliconrepublic.com Follow us on Twitter: https://twitter.com/siliconrepublic Like us on Facebook: https://www.facebook.com/siliconrepublic
At Bristol-Myers Squibb, patients are at the center of everything we do. BMS Tampa is one example of a dynamic workplace working together for patients. Our center in Tampa manages operations in R&D;, Business Operations, Finance, IT, Procurement, Marketing and Human Resources — with more roles still to come. Learn more at http://www.tampa.bms.com. Join Bristol-Myers Squibb Online: Website: https://www.bms.com Twitter: https://www.twitter.com/BMSnews Facebook: https://www.facebook.com/bristolmyerssquibb LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb
Introduction by: Thomas Lynch, MD, CEO, Mass General Physician's Organization Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC Giovanni Caforio, MD, CEO, Bristol-Myers Squibb
Compere Jonathan McCrea speaks with MIke Furlong, Executive DIrector, Cruiserath Biologics, BMS, Mairead Looby, Director, Manufacturing Science and Technology, BMS, Donagh Walls, Associate Director, QC Site Operations, BMS, and Lisa Cahill, HR Manager, BMS.
Lecture delivered on June 17, 2010. This is the first Distinguished Lecture in Immunology supported by Bristol-Myers Squibb. UC Irvine Institute For Immunology presents Michael D. Cahalan, Ph.D., Professor and Chair Department of Physiology and Biophysics Institute for Immunology University of California, Irvine.
Gov. Rick Scott and city and county leaders attended the opening of Bristol-Myers Squibb's North America Capability Center located on Eisenhower Boulevard near Tampa International Airport.
Simeon Taylor, Vice President of R&D; Scientific Affairs at Bristol-Myers Squibb, presented at World Orphan Drug Congress USA 2013 on the topic, 'Drug discovery start point: weighing unmet medical needs, scientific insights and commercial model.' • The role of 'repurposing' as an approach to developing new treatments for rare diseases? • Sources of scientific proposals to repurpose drugs for orphan diseases: patient advocacy organizations, academia, within the pharmaceutical industry itself • What is the optimal timing to identify compounds as candidates for repurposing to treat orphan diseases: during discovery, during development, or as part of life cycle management? World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare dis...
The introduction of Instant JChem and underlying ChemAxon technologies, along with a new data infrastructure designed with analytics in mind, has provided a platform with significantly more flexibility in bringing chemistry and data to the scientist’s desktop. We will discuss the architecture we evolved to and the myriad of new use cases supported by an improved data flow and new ways of looking at the data that have improved decision making, design, and collaboration in drug discovery.
Redacción Médica entrevista a José Cabrera, director médico de Bristol-Myers Squibb.
On March 30, 2016, PPMD and Bristol-Myers Squibb (BMS) hosted a webinar to discuss the BMS Anti-Myostatin Adnectin Program, recent preliminary data from the first-in-human study of the BMS anti-myostatin, and a clinical trial that BMS is conducting to test this drug in boys with Duchenne muscular dystrophy. Visit BMS Study Connect Patient and Care Giver Portal to subscribe for updates on the Duchenne clinical study(s) at http://bmsstudyconnect.com or visit http://clinicaltrials.gov. For any additional questions please call or email BMS at 855-907-3286 / clinical.trials@bms.com.
Morrey Atkinson, Ph.D., Vice President, Process Sciences, Bristol-Myers Squibb presents on “Challenges Associated with Biomanufacturing of Evolving Portfolios” during his plenary keynote presentation at The Bioprocessing Summit 2016 in Boston. Learn more about the event at http://www.bioprocessingsummit.com
Our CEO, Alex Drijver and Ramesh Durvashula, Director for Molecular Sciences, Candidate Optimization & Drug Safety at Bristol-Myers Squibb, are discussing the future of the industry, talking about the hot topics of the cheminformatics.
On November 11, 2015 PPMD hosted a webinar about the importance of myostatin inhibition research. Sponsored by educational partners Bristol-Myers Squibb and Pfizer, this webinar helped to put context and clarity around this treatment pathway so families have a better understanding as they see clinical trials in this area. Some years ago, researchers identified the myostatin pathway as a negative regulator of muscle growth. They isolated the cause of this disparity to a mutation in the gene that codes for the production of a hormone called myostatin, which tends to limit muscle growth. Scientists searching for a treatment theorize that inhibiting myostatin in boys with Duchenne will cause them to develop more muscle mass initially. Ideally, this surplus will offset the muscle loss asso...
Moderator: Thomas Lynch, MD, CEO, Mass General Physician's Organization Francis Cuss, MD, Executive Vice President and Chief Scientific Officer, R&D;, Bristol-Myers Squibb Peter Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen R&D; , J&J; Briggs Morrison, MD, CEO, Syndax Pharmaceuticals Alessandro Riva, MD, Global Head, Oncology Development and Medical Affairs, Novartis Oncology Phil Rowlands, PhD, Interim Head, Oncology, Therapeutic Area Unit, Takeda The many considerations involved in managing a cancer portfolio are among the most important for company vitality and also play a principal role in determining the breadth and rate that new therapies reach patients. Considerations include drug categories (current or potential), use of approved drugs on new tumor types, product...
Stocks covered: Bristol-Myers Squibb (BMY) MEDNAX (MD) Norwegian Cruise Lines (NCLH) Novo Nordisk (NVO)
The Pediatric Otolaryngology Program at The Bristol-Myers Squibb Children’s Hospital (BMSCH) provides the region’s most comprehensive and advanced pediatric otolaryngology services. Our team of pediatric otolaryngologists treats children with disorders involving the ears, nose, and throat with the latest medical guidelines and the most advanced surgical procedures. Learn more at http://www.bmsch.org/hearing.
The 2010 educational seminar series is funded by a grant from: Amgen Oncology, Bristol-Myers Squibb, Genentech BioOncology, Genomic Health, and Sirtex.
Jibe CEO Joe Essenfeld hosts a panel of talent acquisition thought leaders: Heather Tinguely from Microsoft, Semi Trotto from Bristol-Myers Squibb, and Madeline Laurano from The Brandon Hall Group.
Presented by Dr Gary McGeorge of Bristol-Myers Squibb at the world's 1st international pharmaceutical seminar on transmission Raman spectroscopy (held in Oxford in December 2015), this talk focuses on the use of TRS for analysing whole bi-layer tablets and discusses the company's future plans for the methodology.